A PET scan matched MRI in 93% of lesions—what comes next?
Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the U.S. FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. The company's Phase 2b trial showed a 93% concordance between MRI …